Pfizer CFO to step down; Denali sells a regulatory fast-pass

AI Summary

Pfizer's CFO Dave Denton is stepping down, with a search underway for his replacement outside the pharmaceutical industry. Denali has secured venture backing for a new Duchenne gene therapy, and a GSK deal has yielded positive returns.

A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.